{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:18:55Z","timestamp":1789096735701,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.leukres.2006.09.005","type":"journal-article","created":{"date-parts":[[2006,10,15]],"date-time":"2006-10-15T06:56:30Z","timestamp":1160895390000},"page":"1053-1062","source":"Crossref","is-referenced-by-count":35,"title":["Correlations of JAK2\u2013V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders"],"prefix":"10.1016","volume":"31","author":[{"given":"Matthaios","family":"Speletas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisoula","family":"Daiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudokia","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kioumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Ritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Korantzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2006.09.005_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2006.09.005_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2006.09.005_bib3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2006.09.005_bib4","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2006.09.005_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2006.09.005_bib6","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.09.005_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2V671F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.09.005_bib8","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2\u2013V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2006.09.005_bib9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2006.09.005_bib10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2141.2005.05719.x","article-title":"JAK2 V617F mutation is uncommon in chronic myelomonocytic leukemia","volume":"130","author":"Johan","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.09.005_bib11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.09.005_bib12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.09.005_bib13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/sj.leu.2403903","article-title":"Jak2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia","volume":"19","author":"Tono","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2006.09.005_bib14","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.09.005_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2141.2005.05697.x","article-title":"The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukemia","volume":"130","author":"Sulong","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.09.005_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"20","author":"McClure","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2006.09.005_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.leu.2404036","article-title":"Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma","volume":"20","author":"Melzner","year":"2006","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2006.09.005_bib18","first-page":"9","article-title":"Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia","volume":"36","author":"Murphy","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2006.09.005_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1365-2141.1999.01262.x","article-title":"The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia","volume":"104","author":"Barosi","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.09.005_bib20","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/ard.2005.037218","article-title":"Relationship of 5,10-methylenetetrahyrofolate reductase (MTHFR) C677T polymorphism and methotrexate-related toxicity in patients with auoimmune diseases receiving folic acid supplementation","volume":"64","author":"Speletas","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.leukres.2006.09.005_bib21","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.leukres.2006.09.005_bib22","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation based clonality analysis and quantitative JAK2V617F assessement reveals a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.09.005_bib23","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2\u2013V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.09.005_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/10428190500331329","article-title":"A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders","volume":"47","author":"Thiele","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2006.09.005_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1055\/s-0037-1613087","article-title":"Patients with essential thrombocythemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis","volume":"87","author":"Harrison","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.leukres.2006.09.005_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.10054","article-title":"Frequent occurence of anticardiolipin antibodies, factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders","volume":"69","author":"Jensen","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2006.09.005_bib27","first-page":"513","article-title":"Methylenetetrahydrofolate reductase, diet, and risk of colon cancer","volume":"8","author":"Slattery","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prevent"},{"key":"10.1016\/j.leukres.2006.09.005_bib28","doi-asserted-by":"crossref","first-page":"12810","DOI":"10.1073\/pnas.96.22.12810","article-title":"Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults","volume":"96","author":"Skibola","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2006.09.005_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10654-006-9027-8","article-title":"A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia","volume":"21","author":"Zintzaras","year":"2006","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.leukres.2006.09.005_bib30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2006.01.008","article-title":"JAK2 V617F and leukemic transformation in myelofibrosis with myeloid metaplasia","volume":"30","author":"Mesa","year":"2006","journal-title":"Leuk Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606003432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606003432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T16:08:14Z","timestamp":1555862894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212606003432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0145212606003432"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2006.09.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}